The SULSA Assay Development Fund: accelerating translation of new biology from academia to pharma

Stuart P. McElroy; Philip S. Jones; Denise V. Barrault

doi:10.1016/j.drudis.2016.09.028

The SULSA Assay Development Fund: accelerating translation of new biology from academia to pharma

Stuart P. McElroy (Lead / Corresponding author), Philip S. Jones, Denise V. Barrault

Biological Chemistry and Drug Discovery

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

182 Downloads (Pure)

Abstract

With industry increasingly sourcing preclinical drug discovery projects from academia it is important that new academic discoveries are enabled through translation with HTS-ready assays. However, many scientifically interesting, novel molecular targets lack associated high-quality, robust assays suitable for hit finding and development. To bridge this gap, the Scottish Universities Life Sciences Alliance (SULSA) established a fund to develop assays to meet quality criteria such as those of the European Lead Factory. A diverse project portfolio was quickly assembled, and a review of the learnings and successful outcomes showed this fund as a new highly cost-effective model for leveraging significant follow-on resources, training early-career scientists and establishing a culture of translational drug discovery in the academic community.

Original language	English
Pages (from-to)	199-203
Number of pages	5
Journal	Drug Discovery Today
Volume	22
Issue number	2
Early online date	5 Oct 2016
DOIs	https://doi.org/10.1016/j.drudis.2016.09.028
Publication status	Published - Feb 2017

Access to Document

10.1016/j.drudis.2016.09.028Licence: CC BY-NC-ND

Final Published Version
©2016 TheAuthor(s). Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Final published version, 343 KBLicence: CC BY-NC-ND

Fingerprint Dive into the research topics of 'The SULSA Assay Development Fund: accelerating translation of new biology from academia to pharma'. Together they form a unique fingerprint.

Cite this

@article{1592039cdef943a6ad33d692750081d2,

title = "The SULSA Assay Development Fund: accelerating translation of new biology from academia to pharma",

abstract = "With industry increasingly sourcing preclinical drug discovery projects from academia it is important that new academic discoveries are enabled through translation with HTS-ready assays. However, many scientifically interesting, novel molecular targets lack associated high-quality, robust assays suitable for hit finding and development. To bridge this gap, the Scottish Universities Life Sciences Alliance (SULSA) established a fund to develop assays to meet quality criteria such as those of the European Lead Factory. A diverse project portfolio was quickly assembled, and a review of the learnings and successful outcomes showed this fund as a new highly cost-effective model for leveraging significant follow-on resources, training early-career scientists and establishing a culture of translational drug discovery in the academic community.",

author = "McElroy, {Stuart P.} and Jones, {Philip S.} and Barrault, {Denise V.}",

note = "SULSA Assay Development Fund was funded through the Scottish Universities Life Sciences Alliance by a grant award from the Scottish Funding Council (SFC Ref: 240599989)",

year = "2017",

month = feb,

doi = "10.1016/j.drudis.2016.09.028",

language = "English",

volume = "22",

pages = "199--203",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - The SULSA Assay Development Fund

T2 - accelerating translation of new biology from academia to pharma

AU - McElroy, Stuart P.

AU - Jones, Philip S.

AU - Barrault, Denise V.

N1 - SULSA Assay Development Fund was funded through the Scottish Universities Life Sciences Alliance by a grant award from the Scottish Funding Council (SFC Ref: 240599989)

PY - 2017/2

Y1 - 2017/2

N2 - With industry increasingly sourcing preclinical drug discovery projects from academia it is important that new academic discoveries are enabled through translation with HTS-ready assays. However, many scientifically interesting, novel molecular targets lack associated high-quality, robust assays suitable for hit finding and development. To bridge this gap, the Scottish Universities Life Sciences Alliance (SULSA) established a fund to develop assays to meet quality criteria such as those of the European Lead Factory. A diverse project portfolio was quickly assembled, and a review of the learnings and successful outcomes showed this fund as a new highly cost-effective model for leveraging significant follow-on resources, training early-career scientists and establishing a culture of translational drug discovery in the academic community.

AB - With industry increasingly sourcing preclinical drug discovery projects from academia it is important that new academic discoveries are enabled through translation with HTS-ready assays. However, many scientifically interesting, novel molecular targets lack associated high-quality, robust assays suitable for hit finding and development. To bridge this gap, the Scottish Universities Life Sciences Alliance (SULSA) established a fund to develop assays to meet quality criteria such as those of the European Lead Factory. A diverse project portfolio was quickly assembled, and a review of the learnings and successful outcomes showed this fund as a new highly cost-effective model for leveraging significant follow-on resources, training early-career scientists and establishing a culture of translational drug discovery in the academic community.

U2 - 10.1016/j.drudis.2016.09.028

DO - 10.1016/j.drudis.2016.09.028

M3 - Article

C2 - 27720829

VL - 22

SP - 199

EP - 203

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 2

ER -